159727-88-5Relevant academic research and scientific papers
AZA-QUINOLINE COMPOUNDS AND USES THEREOF
-
Page/Page column 40-41, (2021/04/02)
Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
Synthesis of 4-((1H-benzo[d]imidazol-2-yl)oxy)-3-methylpicolinic acid, a key related substance of Rabeprazole sodium
Bao, Xuefei,Chang, Yan,Chen, Guoliang,He, Xiaoyan,Liu, Zi'ao,Lu, Xiuhong
supporting information, (2020/07/03)
4-((1H-benzo[d]imidazol-2-yl)oxy)-3-methylpicolinic acid (11) is a key related substance of Rabeprazole sodium. In this article, this key related substance is synthesized by using 3-methylpicolinonitrile as a starting material via a five-step processes. By converting 3-methylpicolinonitrile to 4-hydroxy-3-methylpicolinonitrile (13), the preparation of TM becomes practical. This work provides a guarantee for quality standard establishment of Rabeprazole sodium.
HETEROARYL OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 65, (2016/07/05)
The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
FLUOROPHENYL PYRAZOL COMPOUNDS
-
Page/Page column 9-10, (2015/07/07)
The present invention provides a compound of the Formula (I), wherein X is selected from the group consisting of (II); R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 and (III); or a pharmaceutically acceptable salt thereof.
FLUOROPHENYL PYRAZOL COMPOUNDS
-
Page/Page column 9; 10, (2015/07/07)
The present invention provides a compound of the Formula: wherein X is selected from the group consisting of, R is selected from the group consisting of H and CH3; R1 is selected from the group consisting of H, CH3, F, Cl, OCH3, C(O)OH, C(O)NH2 or a pharmaceutically acceptable salt thereof.
DIMETHYLBENZOIC ACID COMPOUNDS
-
Page/Page column 23, (2015/07/07)
The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
INHIBITORS OF JANUS KINASES
-
Page/Page column 62, (2010/01/12)
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
